$8.64
1.29% day before yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US4884451075
Symbol
ZVRA

KemPharm, Inc. Stock price

$8.64
-0.01 0.12% 1M
-0.51 5.57% 6M
+0.30 3.60% YTD
+0.05 0.58% 1Y
+4.35 101.40% 3Y
-2.88 25.00% 5Y
-300.32 97.20% 10Y
-170.56 95.18% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.11 1.29%
ISIN
US4884451075
Symbol
ZVRA
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$199.5m
Shares outstanding
56.2m
Valuation (TTM | estimate)
P/E
13.7 | 6.6
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
22.3%
Return on Equity
-266.0%
ROCE
-11.9%
ROIC
-42.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$84.4m | $102.3m
EBITDA
$-23.6m | $-74.7m
EBIT
$-29.0m | $-67.2m
Net Income
$35.3m | $73.4m
Free Cash Flow
$-30.2m
Growth (TTM | estimate)
Revenue
240.4% | 333.3%
EBITDA
70.7% | 7.4%
EBIT
66.4% | 22.7%
Net Income
141.6% | 169.6%
Free Cash Flow
56.6%
Margin (TTM | estimate)
Gross
93.9%
EBITDA
-28.0% | -73.0%
EBIT
-34.3%
Net
41.9% | 71.8%
Free Cash Flow
-35.8%
More
EPS
$0.6
FCF per Share
$-0.5
Short interest
12.3%
Employees
59
Rev per Employee
$400.0k
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

Buy
93%
Hold
7%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
84 84
240% 240%
100%
- Direct Costs 5.16 5.16
5% 5%
6%
79 79
309% 309%
94%
- Selling and Administrative Expenses 73 73
37% 37%
87%
- Research and Development Expense 18 18
59% 59%
22%
-24 -24
71% 71%
-28%
- Depreciation and Amortization 5.34 5.34
3% 3%
6%
EBIT (Operating Income) EBIT -29 -29
66% 66%
-34%
Net Profit 35 35
142% 142%
42%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company's common stock (the “Inducement Awards”) to three new employees pursuant...
Neutral
GlobeNewsWire
24 days ago
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today.
Neutral
GlobeNewsWire
about one month ago
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to ...
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 59
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today